Manufacturer of Controlled Substances; Notice of Application; Johnson Matthey, Inc., 67397-67398 [2012-27398]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 218 / Friday, November 9, 2012 / Notices
67397
July 26, 2012, 77 FR 43861, Boehringer
Ingelheim Chemicals, Inc., 2820 N.
Normandy Drive, Petersburg, Virginia
23805, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
Phenylacetone (8501), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance to bulk
manufacture amphetamine.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Boehringer Ingelheim Chemicals, Inc.,
to import the basic class of controlled
substance is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971.
DEA has investigated Boehringer
Ingelheim, Inc., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above named
company is granted registration as an
importer of the basic class of controlled
substance listed.
Schedule
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 8, 2013.
Dated: November 1, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: November 1, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Allentown, Pennsylvania 18106, made
application to the Drug Enforcement
Administration (DEA) for registration as
an importer of Tapentadol (9780), a
basic class of controlled substance listed
in schedule II.
The company plans to import the
listed controlled substance to conduct
clinical trials.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
listed in schedule II, which falls under
the authority of section 1002(a)(2)(B) of
the Act (21 U.S.C. 952(a)(2)(B)) may, in
the circumstances set forth in 21 U.S.C.
958(i), file comments or objections to
the issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR
§ 1301.43 and in such form as
prescribed by 21 CFR § 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 10, 2012.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e), and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, 40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substances in schedules
I or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR § 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: November 1, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–27437 Filed 11–8–12; 8:45 am]
BILLING CODE 4410–09–P
tkelley on DSK3SPTVN1PROD with NOTICES
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer Of Controlled Substances;
Notice of Registration; Boehringer
Ingelheim Chemicals, Inc.
By Notice dated July 17, 2012, and
published in the Federal Register on
VerDate Mar<15>2010
17:34 Nov 08, 2012
Jkt 229001
[FR Doc. 2012–27440 Filed 11–8–12; 8:45 am]
Drug
Gamma
Hydroxybutyric
Acid
(2010).
Codeine-N-oxide (9053) ...............
Dihydromorphine (9145) ...............
Morphine-N-oxide (9307) .............
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Codeine (9050) II Dihydrocodeine
(9120).
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Sufentanil (9740) ..........................
Carfentanil (9743) .........................
Tapentadol (9780) ........................
Fentanyl (9801) ............................
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
[FR Doc. 2012–27394 Filed 11–8–12; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Noramco, Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 9, 2012,
Noramco, Inc., 1440 Olympic Drive,
Athens, Georgia 30601, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Johnson Matthey, Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 10,
2012, Johnson Matthey, Inc.,
Pharmaceuticals Materials, 900 River
Road, Conshohocken, Pennsylvania
19428, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
E:\FR\FM\09NON1.SGM
09NON1
67398
Federal Register / Vol. 77, No. 218 / Friday, November 9, 2012 / Notices
Drug
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Codeine (9050) .............................
Oxycodone (9143) ........................
Drug
I
II
II
II
II
Schedule
Diphenoxylate (9170) ....................
Hydrocodone (9193) .....................
Meperidine (9230) .........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
Thebaine (9333) ...........................
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution and sale to its
customers.
The Thebaine (9333) will also be used
to manufacture other controlled
substances for sale in bulk to its
customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 8, 2013.
Dated: November 1, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug
Schedule
Dihydromorphine (9145) ...............
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
4-Anilino-N-phenethyl-4-piperidine
(ANPP) (8333).
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans on manufacturing
the listed controlled substances in bulk
for sale to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 8, 2013.
Dated: November 1, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–27398 Filed 11–8–12; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2012–27401 Filed 11–8–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Application,
Cody Laboratories, Inc.
tkelley on DSK3SPTVN1PROD with NOTICES
Drug Enforcement Administration
Drug Enforcement Administration
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 30, 2012,
Cody Laboratories, Inc., ATTN: Richard
Asherman, 601 Yellowstone Avenue,
Cody, Wyoming 82414, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
VerDate Mar<15>2010
17:34 Nov 08, 2012
Jkt 229001
Manufacturer of Controlled
Substances Notice of Application;
National Center For Natural Products
Research (NIDA MPROJECT)
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 17, 2012,
National Center for Natural Products
Research—NIDA MProject, University of
Mississippi, 135 Coy Waller Complex,
University, Mississippi 38677, made
application by renewal to the Drug
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Schedule
I
I
The company plans to cultivate
marihuana for the National Institute on
Drug Abuse for research approved by
the Department of Health and Human
Services.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 8, 2013.
Dated: November 1, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–27441 Filed 11–8–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application; INB
Hauser Pharmaceutical Services, Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 20,
2012, InB Hauser Pharmaceutical
Services, Inc., 6880 N. Broadway, Suite
H, Denver, Colorado 80221, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
4-Anilino-N-phenethyl-4-piperidine
(8333), a basic class of controlled
substance listed in schedule II.
The company plans to manufacture
the listed controlled substance in bulk
for distribution and sale to its
customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
E:\FR\FM\09NON1.SGM
09NON1
]]>Agencies
[Federal Register Volume 77, Number 218 (Friday, November 9, 2012)]
[Notices]
[Pages 67397-67398]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-27398]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application;
Johnson Matthey, Inc.
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on September 10, 2012, Johnson
Matthey, Inc., Pharmaceuticals Materials, 900 River Road, Conshohocken,
Pennsylvania 19428, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
following basic classes of controlled substances:
[[Page 67398]]
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)............ I
Amphetamine (1100).......................... II
Methylphenidate (1724)...................... II
Codeine (9050).............................. II
Oxycodone (9143)............................ II
------------------------------------------------------------------------
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Diphenoxylate (9170)........................ II
Hydrocodone (9193).......................... II
Meperidine (9230)........................... II
Methadone (9250)............................ II
Methadone intermediate (9254)............... II
Morphine (9300)............................. II
Thebaine (9333)............................. II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution and sale to its customers.
The Thebaine (9333) will also be used to manufacture other
controlled substances for sale in bulk to its customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than January 8, 2013.
Dated: November 1, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-27398 Filed 11-8-12; 8:45 am]
BILLING CODE 4410-09-P
